

## **PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025**

PETACH TIKVA, Israel, Jan. 29, 2025 — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter and full-year 2024 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, February 12, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question of management, the Company recommends listening via the webcast.

### **Conference Call Dial-In & Webcast Information:**

Date: Wednesday, February 12, 2025  
Time: 8:30 AM Eastern Time  
Conference  
Call: <https://register.vevent.com/register/BI4e72dffa5a7b4167a28a33a6b3097df3>  
Webcast <https://edge.media-server.com/mmc/p/7uzqoye3>

### **About PolyPid**

PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matrix) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX<sub>100</sub> is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.

For additional Company information, please visit <http://www.polypid.com> and follow us on Twitter and LinkedIn.

References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.

### **Contacts:**

PolyPid Ltd.  
Ori Warshavsky

COO - US  
908-858-5995  
IR@Polypid.com

**Investors:**

Brian Ritchie  
LifeSci Advisors  
212-915-2578  
Britchie@lifesciadvisors.com

